Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.

被引：0

作者：

Ozcan, Muhit

Lee, Seung Tae

Mensah, Felix

Modi, Dipenkumar

Fossa, Alexander

Kim, Won Seog

Paszkiewicz-Kozik, Ewa

Sawalha, Yazeed

Sevindik, Omur Gokmen

Norasetthada, Lalita

Santoro, Armando

Pathiraja, Kumudu

Chakraborty, Samhita

Marinello, Patricia

Lavie, David

机构：

[1] Ankara Univ, Sch Med, Ankara, Turkiye

[2] Univ Maryland Marlene, Baltimore, MD USA

[3] Stewart Green Ebaum Comprehens Canc Ctr, Baltimore, MD USA

[4] Franciscan Hlth, Indiana Blood & & Marrow Transplantat, Indianapolis, IN USA

[5] Karmanos Canc Inst, Detroit, MI USA

[6] Oslo Univ Hosp, Oslo, Norway

[7] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[8] Maria Sklodowska Curie Natl Inst Oncol, Warsaw, Poland

[9] Ohio State Univ, James Canc Hosp & Solove Res Inst, Columbus, OH USA

[10] Istanbul Medipol Univ, Int Sch Med, Istanbul, Turkiye

[11] Chiang Mai Univ, Fac Med, Chiang Mai, Thailand

[12] Humanitas Univ, Pieve & IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy

[13] Merck Co Inc, Rahway, NJ USA

[14] Hadassah Med Ctr, Jerusalem, Israel

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7531

引用

页数：1

共 50 条

[1] Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study
Ozcan, Muhit
Lv, Fangfang
Norasetthada, Lalita
Paszkiewicz-Kozik, Ewa
Schmidt, Joaquin Diaz
Modi, Dipenkumar
Fossa, Alexander
Goyal, Sagun
Kim, Won Seog
Lee, Seung Tae
Santoro, Armando
Sonmez, Mehmet
Pathiraja, Kumudu
Reddy, Nishitha
Marinello, Patricia
Song, Yuqin
BLOOD, 2023, 142
[2] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Kalakonda, Nagesh
Cavallo, Federica
Follows, George
Goy, Andre
Vermaat, Joost S. P.
Casasnovas, Olivier
Lavee, Orly
Maerevoet, Marie
Zijlstra, Josee
Bakhshi, Sameer
Bouabdallah, Reda
Choquet, Sylvain
Gurion, Ronit
Hill, Brian
Jaeger, Ulrich
Sancho, Juan-Manuel
Schuster, Michael
Thieblemont, Catherine
De la Cruz, Fatima
Egyed, Miklos
Mishra, Sourav
Offner, Fritz
Vassilakopoulos, Theodoros
Warzocha, Krzysztof
McCarthy, Daniel
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita
Shah, Jatin
Van den Neste, Eric
Canales, Miguel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
[3] Updated results of a phase Ib/II randomised study: polatuzumab vedotin (Pola) plus bendamustine (B) and rituximab (R) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
Sehn, L. H.
McMillan, A.
Matasar, M. J.
Flowers, C. R.
Kamdar, M.
Hertzberg, M.
Assouline, S.
Kim, T. M.
Kim, W. S.
Ozcan, M.
Croft, B.
Herrera, A. F.
Hirata, J.
Cheng, J.
Ku, G.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 93 - 94
[4] A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.
Westin, Jason R.
Maris, Michael B.
Al-Katib, Ayad M.
Lakhani, Nehal J.
Patel, Prapti Arvind
Harb, Wael A.
McCaul, Kelly
Patel-Donnelly, Dipti
Messmann, Richard Adam
Klencke, Barbara J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Gatwood, Justin
Masaquel, Anthony
Ross, Ryan
Sheinson, Danny
Hossain, Farah
Li, Jia
James, Cameron
Fox, David
BLOOD, 2022, 140 : 7906 - 7907
[6] A Phase 2 Study of Zilovertamab Vedotin With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab (R-CHP) in Diffuse Large B-Cell Lymphoma: waveLINE-007
David, Lavie
Muhit, Ozcan
Ewa, Paszkiewicz-Kozik
Eva, Gonzalez Barca
Min, Kim Tae
Benedetta, Puccini
Siruo, Wang
Rushdia, Yusuf
Patricia, Marinello
Seog, Kim Won
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S31 - S32
[7] Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial
de Vos, Sven
Reagan, Patrick M.
Patel, Manish R.
Saba, Nakhle S.
Mortlock, Andrew
Cerec, Virginie
Munugalavadla, Veerendra
Acar, Melih
Nuttall, Barrett
Jenkins, David
White, Rafael
Callahan, Megan
Forcina, Alessandra
Roschewski, Mark
Flinn, Ian W.
BLOOD, 2022, 140 : 6635 - 6637
[8] A phase 2 study of bortezomib in relapsed/refractory diffuse large B-Cell lymphoma (DLBCL).
de Vos, S
Fernando, D
Schenkein, DP
Rosen, PJ
BLOOD, 2005, 106 (11) : 267B - 267B
[9] waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).
Lavie, David
Ozcan, Muhit
Paszkiewicz-Kozik, Ewa
Barca, Eva Gonzalez
Kim, Tae Min
Puccini, Benedetta
Wang, Siruo
Yusuf, Rushdia
Marinello, Patricia
Kim, Won Seog
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study
Yasenchak, Christopher
Kim, Jeong-A
Hahn, Uwe
Kim, Won-Seog
Fleury, Isabelle
Laribi, Kamel
Bergua Burgues, Juan Miguel
Bouabdallah, Krimo
Forward, Nicholas
Bijou, Fontanet
MacDonald, David
Portell, Craig
Ghesquieres, Herve
Nowakowski, Grzegorz
Rustia, Evelyn
Fanale, Michelle
Jie, Fei
Bartlett, Nancy
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S490 - S491

← 1 2 3 4 5 →